Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.74 |
| ▸ | HTT | P42858 | 10/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 8/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.74 |
| ▸ | NPC1 | O15118 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | ATM | Q13315 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 3/20 | 0.74 |
| ▸ | MITF | O75030 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | XBP1 | P17861 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | CDC25A | P30304 | 3/20 | 0.65 |
| ▸ | CDC25B | P30305 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32664539 | 0.86 | MAPT (0.79) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL6506683 | 0.85 | MAPT (1.00) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL29633261 | 0.85 | MAPT (1.00) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL13417403 | 0.85 | MAPT (0.50) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL1242311 | 0.85 | MAPT (0.67) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL4873496 | 0.83 | MAPT (1.00) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL7240445 | 0.83 | MAPT (0.74) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL4868219 | 0.83 | MAPT (1.00) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL12283294 | 0.80 | MAPT (0.71) | MAPTHTTRAB9ANPSR1MAPK1 | |
| SCHEMBL8654120 | 0.79 | MEN1 (0.65) | MAPTHTTRAB9ANPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2021-08-10 | — | — | US | disclosed |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2021-08-10 | — | — | US | disclosed |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-12-10 | — | — | US | disclosed |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-12-10 | — | — | US | disclosed |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-08-18 | — | — | US | disclosed |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-08-18 | — | — | US | disclosed |
| EP-3328368-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | BRIDGENT BIOTECHNOLOGY INC (TW) | 2020-07-15 | — | — | EP | disclosed |
| EP-3328368-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | BRIDGENT BIOTECHNOLOGY INC (TW) | 2020-07-15 | — | — | EP | disclosed |
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2019-05-16 | — | — | US | disclosed |
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2019-05-16 | — | — | US | disclosed |
| WO-2017020030-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-02-02 | — | — | WO | disclosed |
| US-9272993-B2 | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2016-03-01 | — | — | US | disclosed |
| US-9272993-B2 | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2016-03-01 | — | — | US | disclosed |
| US-20140213627-A1 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2014-07-31 | — | — | US | disclosed |
| US-20140213627-A1 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2014-07-31 | — | — | US | disclosed |
| US-20110224184-A1 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2011-09-15 | — | — | US | disclosed |
| US-20110224184-A1 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2011-09-15 | — | — | US | disclosed |
| WO-2010026592-A1 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-03-11 | — | — | WO | disclosed |
| EP-0866692-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA Société Anonyme (FR) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997021432-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA, S.A. (FR) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | PSMC1, PSME3, PSMB1 | MAPT 308/4885HTT 209/4885RAB9A 1884/4885 |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | PSMC1, PSME3, PSMB1 | MAPT 308/4885HTT 209/4885RAB9A 1884/4885 |
| US-20140213627-A1 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS | APP, PSEN1, PSEN2 | MAPT 14/4885HTT 13/4885RAB9A 2597/4885 |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | PSMC1, PSME3, PSMB1 | MAPT 308/4885HTT 209/4885RAB9A 1884/4885 |
| US-20110224184-A1 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS | APP, PSEN1, PSEN2 | MAPT 14/4885HTT 13/4885RAB9A 2597/4885 |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | PSMC1, PSME3, PSMB1 | MAPT 308/4885HTT 209/4885RAB9A 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.